Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •Uncontrolled metastasis in the CNS
• •Acute, heavy uncontrolled infection
• •Any other serious concomitant disease or medical condition, which could interfere with participating in this study
• •Severe hypersensitivity to Erlotinib or any other component
• •Hypersensitivity to Carboplatin and/or other platinum compounds
• •Hypersensitivity to Vinorelbin or other Vinca-alkaloids
• •Patients with a history of other active malignancy in the past 5 years (with the exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma that was surgically treated successfully) are excluded.
• •Participation in another clinical trial with any investigational drug at the same time or within 30 days prior to registration
• •Psychological, familial, social or geographical situations limiting the compliance with the study requirements